ArticleBMC public health2026
Characterizing HIV-related patient portal preferences among men who have sex with men in the United States.
Article in BMC public health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGay, bisexual, and other men who have sex with men (MSM) remain disproportionately affected by sexually transmitted infections (STIs), including HIV, in the United States. Patient-facing digital tools, such as patient portals, can enhance STI prevention and care if designed to align with user needs and preferences. Thus, this study examined interest in specific portal features across various segments of MSM communities.
methodsData were drawn from the 2022-2023 cycle of the American Men's Internet Survey. A randomized subset of participants was asked about interest in four portal features: (A) easier interpretation of lab results, (B) behavioral guidance after positive STI results, (C) ability to order HIV/STI home test kits, and (D) education on undetectable HIV viral load and transmission. To measure associations of sociodemographic, behavioral, and psychosocial variables with these multivariate feature interest outcomes we estimated adjusted prevalence ratios (aPRs) using multivariable Poisson regression models with robust error variance.
resultsThe final analytic sample included 3,495 MSM (median age = 44 years; 70% White; 13% self-reported as living with HIV). Interest was highest for easier lab interpretation (64%), followed by behavioral guidance (43%), home test kit ordering (36%), and education on undetectable viral load (36%). Adjusted prevalence ratios for endorsing the integration of Undetectable=Untransmittable (U = U) education into portals was 24% (95%CI = 1.07, 1.45) and 37% (95%CI = 1.18, 1.60) higher among Black and Hispanic/Latino participants compared to White participants. Reporting anticipated healthcare stigma (aPR = 1.53; 95%CI = 1.33, 1.76) and socio-sexual networking app use (aPR = 1.17; 95%CI = 1.03, 1.32) were associated with greater interest in home test kits. People living with HIV (PLHIV) expressed lower interest in home test kits (aPR = 0.64; 95%CI = 0.53, 0.77) but higher interest in U = U education (aPR = 1.72; 95%CI = 1.96). Similarly, reporting suicidal thoughts was associated with a 19% higher aPR for interest in the inclusion of U = U education.
conclusionsMSM broadly support patient portal features that enhance understanding of health information, provide actionable guidance, and facilitate testing and education. The variability in preferences by HIV status, age, race/ethnicity, stigma experiences, and mental health underscore the need for tailored design and implementation of digital health tools among MSM communities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.